RecruitingPhase 2NCT05425004

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Studying Meningioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Baptist Health South Florida
Principal Investigator
Rupesh Kotecha, M.D.
Miami Cancer Institute at Baptist Health, Inc.
Intervention
Cabozantinib(drug)
Enrollment
24 enrolled
Eligibility
18 years · All sexes
Timeline
20222028

Study locations (3)

Collaborators

Exelixis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05425004 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma

← Back to all trials